Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV

Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV

Two-drug regimens (2DRs) are emerging in clinical practice guidelines as treatment option for both naive and treatment-experienced people living with HIV (PLHIV). <b>Objectives:</b> To determine the real-life effectiveness of 2DR with 25 mg RPV plus 50 mg DTG in a single-tablet regimen (...

Full description

Bibliographic Details
Main Authors: Carmen Hidalgo-Tenorio, David Vinuesa, Coral García-Vallecillos, Leopoldo Muñoz-Medina, Sergio Sequera, Rosario Javier, Miguel Ángel López-Ruz, Svetlana Sadyrbaeva-Dolgova, Juan Pasquau
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Viruses
Subjects:
2DR
dolutegravir
rilpivirine
treatment-experienced PLHIV
Online Access:https://www.mdpi.com/1999-4915/14/12/2626

Internet

https://www.mdpi.com/1999-4915/14/12/2626

Similar Items